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Abstract
Background: The incidence of Penicillium marneffei infection has recently increased. This fungus can cause fatal
systemic mycosis in both immunocompetent and immunocompromised patients without HIV infection.
Methods: We retrospectively analysed Penicilliosis patients between January 1, 2003 and August 1, 2014 at the First
Affiliated Hospital of Guangxi Medical University. HIV-negative patients with Penicilliosis were divided into two groups:
patients with underlying disease (Group D) and patients without underlying disease (Group ND). HIV-positive patients
were excluded. The relationships between overall survival and the study variables were assessed using univariate and
multivariate analyses.
Results: During 11 years, Penicillium marneffei infection was diagnosed in 109 patients. Sixty-six (60.55 %) patients were
HIV-positive and excluded from these cases. Forty-three patients were HIV-negative were enrolled. Among these
patients, 18 (41.86 %) patients were in Group D, and 25 (58.14 %) were in Group ND. The most common underlying
disease was diabetes. There were no statistically significant differences between the two groups in clinical
characteristics, except for immune state and prognosis. Group ND had higher lymphocyte cell counts, CD4 cell
counts, and CD4 T-cell percentages than Group D (P < 0.05). Patients in Group D had higher recurrence and
mortality rates than Group ND (P < 0.05). In the univariate analysis, only underlying disease, CD4 cell percentage,
and T lymphocyte cell percentage were significantly associated with overall survival.
Conclusions: Penicillium marneffei can infect HIV-negative patients and can cause fatal systemic mycosis. There
were no clear differences in clinical manifestations among HIV-negative patients with and without underlying
disease. However, Penicillium marneffei in HIV-negative patients in with underlying diseases may cause immune
function decline and a deficiency in T-cell-mediated immunity. Underlying disease, CD4 cell percentage, and T
lymphocyte cell percentage may be potential risk factors affecting prognosis. Timely, effective, and longer courses of
antifungal treatments are important in improving prognoses.
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Background
Penicillium marneffei is capable of causing fatal systemic
mycosis in immunocompromised individuals, especially
in HIV-positive patients [1–3]. However, the incidence
of Penicillium marneffei infection in both immunocom-
petent and immunocompromised patients without HIV
infection has shown a marked increase in recent years
[3]. Penicillium marneffei infection can cause immune
function decline and deficiency in T-cell-mediated im-
munity even in a healthy host, such as haematological
malignancies, colon cancer, myasthenia gravis, mixed
connective tissue disease, transplant rejection, systemic
lupus erythematosus, diabetes mellitus, and corticoste-
roids or immunosuppressive agents [3, 4]. There are nu-
merous retrospective studies investigating the differences
of penicilliosis among patients with and without HIV
infection [3–8]. However, no studies have observed differ-
ences in Penicillium marneffei infection among HIV-
negative patients with and without underlying disease.
This retrospective study is the first time to describe dif-
ferences in clinical features, immune status, treatment,
and outcomes and to elucidate the important factors
that influence successful treatment and prognosis of




A retrospective study was conducted between January 1,
2003 and August 1, 2014 at the First Affiliated Hospital
of Guangxi Medical University. Consecutive patients di-
agnosed with Penicilliosis were eligible. HIV-negative pa-
tients with Penicillium marneffei infection were included
and divided into two groups: patients with underlying
disease (Group D) and those without underlying disease
(Group ND). Patients who were HIV-positive were ex-
cluded. The patients’ clinical records were reviewed for
basic information, medical history, auxiliary examination
results, and treatments, and summarised for analysis.
This study was approved by the Faculty of Medicine, The
First Affiliated Hospital of Guangxi Medical University
Table 1 Underlying disease and demographic data of HIV-






Age, years 42.5 (1–68) 38.74y
(2–64)
0.348
Male 14 (77.78 %) 16 (64 %)
Underlying diseases* 18 (100 %) 0
Diabetes 6 (33.33 %) 0
Lymphoma 1 (5.56 %) 0
β-thalassemia 2 (11.11 %) 0
Breast cancer 1 (5.56 %) 0
Previous glucocorticoid therapy 1 (5.56 %) 0
Langerhans cell histiocytosis 1 (5.56 %) 0
G-6PD deficiency 1 (5.56 %) 0
Systemic lupus erythematosus 1 (5.56 %) 0
Subacute thyroiditis 1 (5.56 %) 0
Chronic hepatitis B 2 (11.11 %) 0
Hyperthyroidism 2 (11.11 %) 0
Data are presented as n (%). *One patient may have ≥ 1 underlying diseases
Patients with Penicillium marneffei infection were divided into two groups;
Group D includes patients with underlying disease, and Group ND includes
patients without underlying disease
Table 2 Clinical features of penicilliosis among HIV-negative patients with and without underlying disease
Variables Group D (N = 18) Group ND (N = 25) P-values
Fever 17 (94.4 %) 22 (88 %) 0.853
Mean temperature 39.58 °C 39.67 °C 0.971
Lymphadenopathy 16 (88.9 %) 18 (72 %) 0.336
Hepatomegaly 10 (55 %) 7 (28 %) 0.068
Splenomegaly 9 (50 %) 7 (28 %) 0.141
Cutaneous lesions 14 (77.8 %) 16 (64 %) 0.332
Cough 15 (83.3 %) 23 (92 %) 0.695
Dyspnoea 6 (33.3 %) 8 (32 %) 0.972
Anaemia 16 (88.9 %) 24 (96 %) 0.767
Osteolysis 8 (44.4 %) 6 (24 %) 0.158
Thoracalgia 8 (44.4 %) 4 (16 %) 0.040*
Bloody stools/diarrhoea 5 (27.7 %) 4 (16 %) 0.578
Duration of diagnosis (days) (median, IQR) 135.5 (27–1008) 102 (12–635) 0.079
Data are presented as n (%) or median (IQR), unless indicated otherwise
*P < 0.05
Patients with Penicillium marneffei infection were divided into two groups; Group D included patients with underlying disease, and Group ND included patients
without underlying disease
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Ethical Committee. All patients provided written in-
formed consent.
Diagnosis criteria for Penicillium marneffei infection
There were two methods used for pathological and
pathogen examination. In the first method, cultures of
clinical specimens, including blood, sputum, lymph node,
lung tissue, bone, and bone marrow, were established on
Sabouraud’s dextrose agar at 25 °C and 37 °C. Positive cul-
tures for Penicillium marneffei were characterised by di-
morphic fungi that grew as a mould at 25 °C and as yeast
at 37 °C. A unique characteristic of Penicillium marneffei
mould is the presence of a soluble red pigment that dif-
fuses into the agar making the reverse side appear either
pink or red at 25 °C [2].
For the second method, the yeast form of Penicillium
marneffei was identified by cytology and histopathology
from tissues and secretions by periodic acid-Schiff staining
or Wright’s staining. Penicillium marneffei has a charac-
teristic morphology, including a transverse septum [6].
Patients’ sera were tested in duplicate at our hospital
and the Guangxi Center for Prevention and Control by
using enzyme-linked immunosorbent assay (Enzymun-
Test Anti-HIV 1 + 2; Boehringer Mannheim GmbH Diag-
nostica) and particle agglutination test (Serodia-HIV;
Fujirebio Inc., Tokyo, Japan).
Inclusion and exclusion criteria
Inclusion criteria were as follows: i) HIV negative; and ii)
a clear diagnosis of Penicillium marneffei infection.
Patients diagnosed with Penicillium marneffei infection
but who were HIV-positive were excluded.
Statistical analysis
Clinical data were analysed as percentages (%), means
and standard deviations, and medians and interquartile
ranges, as appropriate. Comparison of the demographic
data and clinical characteristics of HIV-negative patients
with and without underlying diseases was performed
using the Student’s t-test, Mann–Whitney U test, chi-
square test, or Fisher’s exact test, as appropriate. Survival
curves were estimated using Kaplan-Meier analyses, and
the differences in survival rates between the two groups
were compared using the log-rank test. Univariate ana-
lysis was performed to assess significant differences in
clinical characteristics that influence overall survival.
Multivariate analysis was performed using Cox regres-
sion analysis for significant variables identified by the
univariate analysis. All statistical analyses were performed
using the Statistical Package for the Social Sciences (Win-
dows version 16.0; SPSS Inc., Chicago, IL, US). Two-tailed




During the study period of 11 years, 109 patients were
diagnosed with Penicillium marneffei infection. Sixty-six
(60.55 %) patients were HIV-positive and excluded from
this case series. The 43 (39.45 %) remaining patients
were HIV-negative and were enrolled in this study.
Among these patients, 18 patients (41.86 %) had under-
lying disease, most commonly diabetes, and were in-
cluded in Group D; the 25 (58.14 %) remaining patients
were in Group ND. Table 1 compares underlying disease
and demographic data between the two groups.
Clinical features
Table 2 shows the common clinical manifestations in all
HIV-negative patients, including anaemia (40 patients,
93 %), hyperpyrexia (39 patients, 90.6 %), cough (38 pa-
tients, 88.3 %), lymphadenopathy (34 patients, 79 %),
Fig. 1 Skin lesions associated with Penicillium marneffei infection. Chronic ulcers a, pustular psoriasis b, and subcutaneous abscesses c
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Table 3 Laboratory findings of penicilliosis among HIV-negative patients with and without underlying disease
Variables Group D (N = 18) Group ND (N = 25) P-values
White blood cells (× 109 cells/L) 22.26 (1.89–57.48) 21.56 (5.6–49.7) 0.846
Neutrophils 16.98 (0.67–46.1) 16.53 (3.62–37.87) 0.888
Lymphocyte cells (× 109 cells/L) 1.75 2.88 0.023*
Haemoglobin (g/L) 90.55 ± 21.9 85.75 ± 21.5 0.479
Platelet count (× 109 cells/L) 274.58 (2.6–516) 284 (18–644) 0.493
ALT (U/L) 37.25 35.36 0.979
ALB (g/L) 19.72 23.33 0.325
CD4 T cell count (cells/L) 255.6 623.66 0.000*
CD8 T cell count (cells/L) 389.43 205.00 0.335
CD4% 26.26 34.40 0.004*
CD8% 26.11 23.25 0.394
T cell% 56.51 66.76 0.019*
IgG 25.37 23.58 0.805
Positive cultures 14 22 0.633
-Blood 6/13 6/14 1.000
-Lymph node 0 1/2
-BAL fluid/lung tissue 0 1/6
-Bone marrow 2/5 2/5 1.000
-Skin 3/5 4/5 1.000
-Sputum 1/6 1/6 1.000
-Purulent secretions 2/7 7/8 0.041*
Positive histopathology 9 11 0.697
-Lymph node 3/7 3/10 0.644
-Bone marrow/bone 3/7 2/4 1.000
-Skin 3/3 3/10 0.392
-Lung tissue 0/3 2/4 0.286
Patients with Penicillium marneffei infection were divided into two groups; Group D included patients with underlying disease, and Group ND included patients
without underlying disease
ALB serum albumin, ALT alanine aminotransferase, CD4% CD4 cell percentage, CD8% CD8 cell percentage, T cell% T lymphocyte cell percentage, IgG serum
immunoglobulin G. Data are presented as the number of observations or the mean ± standard deviation. *P < 0.05
Table 4 High-resolution computed tomography characteristics of penicilliosis among HIV-negative patients with and without under-
lying disease
Variables Group D (N = 18) Group ND (N = 25) P-values
-Normal 4 (22.22 %) 2 (8 %) 0.218
-Interstitial infiltration 9 (50 %) 9 (36 %) 0.359
-Alveolar infiltration 10 (55.56 %) 13 (52 %) 0.818
-Pleural effusion 9 (50 %) 12 (48 %) 0.897
-Cavitary lesion 3 (16.67 %) 1 (4 %) 0.158
-Peritoneal effusion 6 (33.33 %) 8 (32 %) 0.927
Osteolytic bone destruction 8 (44.44 %) 6 (24 %) 0.198
Patients with Penicillium marneffei infection were divided into two groups; Group D included patients with underlying disease, and Group ND included patients
without underlying disease
Data are presented as n (%)
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cutaneous lesions (30 patients, 69.7 %), hepatomegaly (17
patients, 39.5 %), and splenomegaly (16 patients, 37.2 %).
The patients in Group ND more commonly exhibited
thoracalgia than those in Group D (P < 0.05). Cutaneous
lesions consisted of skin rash (Fig. 1a), chronic ulcers, pus-
tular psoriasis (Fig. 1b–c), subcutaneous abscess, pannicu-
litis, and subcutaneous nodules. Symptoms and the the
mean time since diagnosis did not differ between the two
groups (P > 0.05). However, patients in Group D usually
exhibited skin rash distributed over the whole body, while
those in Group ND presented with skin ulcers and sub-
cutaneous nodules limited to the face, neck, or limbs.
Laboratory findings
All cases involved anaemia, and 17 patients had de-
creased platelets (Table 3). The number of white blood
cells and neutrophils increased remarkably in both
groups and did not differ significantly between groups
(P > 0.05). However, Group ND had significantly more
lymphocyte cells than Group D (P = 0.023). The CD8 cell
counts, CD8 T-cell percentages, and serum immuno-
globulin levels did not differ between the two groups (P >
0.05). The mean CD4 cell count was below the normal
level in Group D. Furthermore, Group D had fewer
lymphocyte cells, CD4 cells, and a lower CD4 T-cell per-
centage than Group ND (P < 0.05). The most common
method of diagnosis was cultures from biopsy tissues and
secretions, followed by biopsy pathology, bone marrow
cultures, and blood cultures. Positive cultures and histo-
pathology in clinical specimens, including blood, lymph
node, bronchoalveolar lavage fluid, lung tissue, bone mar-
row, bone, and skin, did not differ between groups (P >
0.05). However, purulent secretion cultures had a higher
positive rate in Group ND than in Group D (P < 0.05).
Imaging examinations
Serous effusion was present in 35 (81.39 %) cases,
mainly in the chest or abdominal cavity, though it also
occurred in the pericardium and pelvic areas. The effu-
sion was positive for the Rivalta test, with an increase in
the number of nucleated cells, suggesting exudate effu-
sion. High-resolution computed tomography (Table 4)
showed interstitial infiltration (Fig. 2a); alveolar infiltration
was most common, including patchy opacities, fibrous
Fig. 2 High-resolution computed tomography. High-resolution computed tomography shows interstitial infiltration and alveolar infiltration a,
a cavitary lesion (arrow) b, and pleural effusion c
Fig. 3 Imaging examinations. Multiple spots or patchy farfetched like bone destruction, periosteal proliferation, fracture, and swelling in
surrounding soft tissue was shown via radiography a & b, emission computed tomography, high resolution computed tomography c, and
positron emission tomography/computed tomography d
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cord proliferation, cavitary lesions (Fig. 2b), mediastinal
lymph nodes, and pleural effusion (Fig. 2c).
Osteolytic bone destruction in 14 (32.55 %) cases (8
patients in Group D and 6 in Group ND) was accom-
panied by pain and dysfunction. Multiple spots or patchy
farfetched bone destruction, periosteal proliferation, frac-
ture, and swollen surrounding soft tissue were present
in X-ray images (Fig. 3a–b), emission computed tomog-
raphy bone scans, high-resolution computed tomog-
raphy (Fig. 3c), and positron emission tomography/
computed tomography (Fig. 3d). After effective anti-
fungal treatment, fractures typically healed within two
months, and the patchy lesions were absorbed.
Antifungal therapy and outcomes
Four patients in Group D and 2 patients in Group ND
ceased antifungal treatment due to serious complications
related to Penicillium marneffei infection, including mul-
tiple organ failure and acute respiratory failure. Among
all 43 cases, 37 received antifungal treatment. The ma-
jority of patients in this study were treated with intra-
venous amphotericin B or fluconazole followed by oral
itraconazole (Table 5). The mortality rate was 44.44 % (8
patients) and 12 % (3 patients) among those with and
without underlying disease, respectively. Recovery oc-
curred in 33.33 % (6 patients) and 28 % (7 patients) of
patients with and without underlying disease, respect-
ively. The longest duration before relapse was 4 years.
Causes of death for 8 patients in Group D included Peni-
cillium marneffei (n = 2), acute respiratory failure (n = 1),
and multiple organ failure (n = 5). The cause of death for
3 patients in Group ND was discontinuing treatment
because of multiple organ failure. Compared to Group
ND patients, Group D patients had higher recurrence and
mortality rates (P = 0.022).
Overall survival
At the median follow-up of 580.95 days (range, 4–
2,345 days), 21 patients (48.83 %) remained alive. To
identify predictors of survival, the prognostic values of
27 variables were evaluated (Table 6). In the univariate
analysis, only underlying disease, CD4 cell percentage,
and T lymphocyte cell percentage were significantly as-
sociated with overall survival (P < 0.05; Table 1). The
long-term survival was significantly better for patients
without underlying disease than for patients with under-
lying disease (log-rank test: P = 0.014; Fig. 4). Patients
with CD4 cell percentage ≥ 31.98 % had better long-term
survival than did patients with CD4 cell percentage <
31.98 % (log-rank test: P = 0.015; Fig. 5). Also, patients
with T lymphocyte cell percentage ≥ 64.2 % had better
long-term survival than did patients with T lymphocyte
cell percentage < 64.2 % (log-rank test: P = 0.019; Fig. 6).
In the multivariate Cox regression analysis, underlying
disease, CD4 cell percentage, and T lymphocyte cell
percentage were significantly associated with overall sur-
vival (P > 0.05; Table 6).
Discussion
Penicilliosis has been reported in immunocompromised
patients with HIV infection, but also in patients free of
HIV infection. Certain diseases can cause immune func-
tion decline and immune disorders, such as haemato-
logical malignancies, colon cancer, myasthenia gravis,
mixed connective tissue disease, transplant rejection,
systemic lupus erythematosus, diabetes mellitus, as well
as the use of corticosteroids or immunosuppressive
Table 5 Treatment outcomes among HIV-negative patients with and without underlying disease
Variables Group D (N = 18) Group ND (N = 25) P-values
Treatment received 14 23 0.378
Deterioration (discontinue treatment) 4 2
Medication
-Amphotericin B then itraconazole 5 6 1.000
-Itraconazole 4 2 0.378
-Fluconazole then itraconazole 4 10 0.220
-Voriconazole 1 5 0.367
Outcome, n (%) 0.022*
-Cure 5 (27.78) 13 (52 %)
-Recovery 6 (33.33 %) 7 (28 %)
-Dead 8 (44.44 %) 3 (12 %)
Patients with Penicillium marneffei infection were divided into two groups; Group D included patients with underlying disease, and Group ND included patients
without underlying disease
*P < 0.05
Data are presented as the number of patients, unless otherwise indicated
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agents, even in HIV-negative [3, 4]. The incidence of
Penicillium marneffei infection in patients without HIV
infection has shown a marked increased in recent years
[3, 5–8]. In our study, during an 11-year period, Penicil-
lium marneffei infection was present in 43 (43/109,
39.45 %) patients without HIV infection. Among these
patients, 41.86 % had underlying diseases, with diabetes
being the most common; 58.14 % had no underlying dis-
eases, which suggests that Penicillium marneffei infection
is not a rare entity, but is also common in HIV-negative
individuals and even healthy hosts.
The common clinical manifestations among HIV-
negative patients were similar to those in previous re-
ports [6]. However, there were no statistically significant
differences between Group D and Group ND in clinical
manifestations and laboratory findings, with the excep-
tion of thoracalgia, which was more common in HIV-
negative patients with underlying disease (P < 0.05).
Previous work has postulated that deficiency of CD4+
T-cell-mediated immunity plays a key pathogenic role in
AIDS patients and may also be involved in immunocom-
promised HIV-negative patients, potentially leading to
Penicillium marneffei infection [6–9]. In our study, CD8
T-cell counts, CD8 T-cell percentages, and serum im-
munoglobulin levels did not differ between the two
groups (P > 0.05). However, HIV-negative patients with-
out underlying disease had higher lymphocyte cell
counts, CD4 cell counts, and CD4 T-cell percentages
than those with underlying disease. The mean CD4 cell
count was below normal levels in HIV-negative patients
Table 6 Univariate and multivariate analyses of factors predicting recurrence-free survival of penicilliosis among HIV-negative patients
Factor Univariate Multivariate
HR 95 % CI P HR 95 % CI P
Age > 60 or < 3 years 0.700 0.274–1.792 0.457
Underlying diseases 0.228 0.064–0.813 0.014* 0.289 0.074-1.132 0.075
Fever 0.300 0.065–1.378 0.122
Lymphadenopathy 2.074 0.601–7.155 0.249
Hepatomegaly 0.374 0.118–1.185 0.095
Splenomegaly 0.606 0.217–1.697 0.341
Cutaneous lesions 0.575 0.225–1.471 0.248
Cough 6.568 0.861–50.100 0.069
Dyspnoea 1.265 0.479–3.344 0.635
Anaemia 1.525 0.439–5.303 0.507
Osteolysis 0.581 0.209–1.618 0.299
Thoracalgia 1.204 0.453–3.200 0.710
Bloody stools/diarrhoea 1.122 0.326–3.869 0.855
Duration of diagnosis 1.026 0.405–2.597 0.957
WBC > 10*109/L 0.628 0.181–2.177 0.463
Neutrophils > 6.3*109/L 0.573 0.205–1.604 0.289
Lymphocytes < 1.10*109/L 2.093 0.730–6.004 0.169
Haemoglobin < 130 g/L 1.082 0.410–2.855 0.874
ALT > 45U/L 2.941 0.608–14.230 0.180
ALB < 55U/L 1.274 0.288–5.627 0.749
CD4 < 410/ul 1.003 0.998–1.008 0.289
CD8 < 190 /ul 0.994 0.985–1.002 0.146
CD4% < 31.98 % 3.033 1.186–7.754 0.015* 1.224 0.305–4.921 0.775
CD8% < 20.70 % 0.654 0.256–1.121 0.374
T cell% < 64.2 % 2.963 1.146–7.659 0.019* 1.950 0.504–7.539 0.333
IgG < 7 g/L 0.800 0.181–3.536 0.769
Chest imaging 0.708 0.251–1.999 0.515
Patients with Penicillium marneffei infection were divided into two groups; Group D included patients with underlying disease, and Group ND included patients
without underlying disease
ALB serum albumin, ALT alanine aminotransferase, CI confidence interval, HR hazard ratio, WBC white blood cell, CD4 CD4 T cell count, CD8 CD8 T cell count,
CD4% CD4 cell percentage, CD8% CD8 cell percentage, T cell% T lymphocyte cell percentage, IgG serum immunoglobulin G. *P < 0.05
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with underlying disease. In addition, in the univariate
analysis, only underlying disease, CD4 cell percentage,
and T lymphocyte cell percentage were significantly as-
sociated with overall survival. Thus, HIV-negative pa-
tients with underlying disease, such as cancer, mixed
connective tissue disease, transplant rejection, systemic
lupus erythematosus, diabetes mellitus, and Langerhans
cell histiocytosis, and those taking corticosteroids or
immunosuppressive agents, exhibited worse CD4 T-
cellular immunodeficiency during the course of the
disease than HIV-negative patients without underlying
disease. Browne et al. and Lee et al. reported that autoanti-
body to interferon-ɤ is associated with the new clinical
syndrome of adult-onset immunodeficiency [8, 10, 11].
This may be another cause of cell-mediated immunity de-
fects in patients who are not infected with HIV. This also
suggests that underlying disease, CD4 cell percentage, and
T lymphocyte cell percentage may be potential risk factors
affecting prognosis.
Specifically, 32.5 % of patients had osteolytic lesions,
and all of these were HIV-negative individuals; no HIV-
positive patients exhibited such lesions. Thus, osteolytic
lesions are one of the most common and important
clinical characteristics of Penicillium marneffei infection,
which can easily be neglected in HIV-negative patients
[12]. Serous effusions are often thought to reflect
hypoalbuminaemia, connective tissue disease, or tuber-
culosis. However, in our study, 81.39 % of patients had
multi-exudate effusion, which suggests that exudate ef-
fusions are equally common in Penicillium marneffei
infection in HIV-negative individuals. However, the
mechanism by which effusion is generated is unclear;
the cause may be inflammation initiated by dissemi-
nated Penicillium marneffei infection, or may directly
involve the thoracic cavity.
The most common diagnostic method of Penicilliosis
was cultures from biopsy tissues and secretions, followed
by biopsy pathology, bone marrow cultures, and blood
cultures, which is consistent with the presence of skin
lesions and lymph node lesions. Histopathology showed
not only classic yeast-like fungi in proliferative macro-
phages, but also granulomas, gaseous necrosis, and small
abscesses, suggesting that the immune system can play a
defensive role.
There were relatively few cases of Penicillium marnef-
fei infection among HIV-negative patients with and
Fig. 4 Overall survival of patients with and without underlying disease. The difference between the two groups was statistically significant (log-
rank test: P = 0.014)
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without underlying disease. The current recommenda-
tion for severe disease in HIV-positive patients is intra-
venous amphotericin B at a dosage of 0.6 mg∙kg−1∙d−1
for 2 weeks, followed by oral itraconazole 200 mg twice
daily for 10 weeks. For mild disease, the recommenda-
tion is oral itraconazole at a dose of 200 mg twice daily
for 8–12 weeks [6].
In this study, we found that HIV-negative patients
with underlying disease had a worse prognosis and
greater treatment difficulty than those without under-
lying disease. The reason for this is that HIV-negative
patients with underlying disease have more obvious im-
mune deficiency and CD4+ T cell-mediated immune de-
ficiency than patients without underlying disease. Some
diseases have the potential to damage immune function,
especially CD4 T-cellular immune function. The majority
of patients in this study received treatment for Penicillium
marneffei infection with intravenous amphotericin B at a
dosage of 0.6 mg∙kg−1∙d−1 for 4–8 weeks, followed by oral
itraconazole or fluconazole 200 mg twice daily for 6–12
months, even treated for up to 2 years, which was signifi-
cantly longer than the current recommendation for severe
disease in HIV-positive patients. Oral itraconazole at a
dosage of 200 mg once daily has been recognised as sec-
ondary prophylaxis. Thus, timely, effective, and longer
courses of antifungal treatment, combined with support of
the immune system, are important to improve patient
prognosis. The longest duration for relapse was 4 years in
this study; therefore, longer-term secondary prophylaxis
and follow-up may be necessary to prevent relapse and
improve prognosis. The important factors to assess when
to discontinue secondary prophylaxis treatment include
lymphocyte cell counts, CD4 cell counts, CD4 T-cell
percentages, lung and bone imaging, and negative culture
of clinical specimens.
Conclusion
Penicillium marneffei can infect individuals without HIV
infection and can cause fatal systemic mycosis. There
were no clear differences in clinical manifestations
among HIV-negative patients with and without under-
lying disease. However, Penicillium marneffei in patients
without HIV infection, in combination with certain dis-
eases, may cause immune function decline and a defi-
ciency in T-cell-mediated immunity during the course of
the disease. Underlying disease, CD4 cell percentage,
and T lymphocyte cell percentage may be potential risk
factors affecting prognosis. Timely, effective, and longer
courses of antifungal treatments, in combination with
Fig. 5 Overall survival of patients with CD4 cell percentage > 31.98 % and≤ 31.98 %. The difference between the two groups was statistically
significant (log-rank test: P = 0.015)
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treatments to improve immune function, are important
in improving prognoses.
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tients for publication of this article and any accompany-
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